The global First-in-Human (FIH) Services market size is predicted to grow from US$ 667 million in 2025 to US$ 1299 million in 2031; it is expected to grow at a CAGR of 11.7% from 2025 to 2031.
First-in-Human Services refer to specialized services that support the planning, execution, and management of First-in-Human (FIH) clinical trials. These services are critical for the successful transition of a drug or therapeutic product from preclinical development to initial testing in human subjects. FIH trials are typically the first time a new drug is administered to humans, making the associated services essential for ensuring safety, compliance, and scientific validity.First-in-Human Services are essential for minimizing risks associated with the early testing of new drugs in humans, ensuring regulatory compliance, and generating reliable data that can influence subsequent phases of drug development. These services help streamline the clinical trial process, improve efficiency, and enhance the likelihood of successful product development.
United States market for First-in-Human (FIH) Services is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for First-in-Human (FIH) Services is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for First-in-Human (FIH) Services is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key First-in-Human (FIH) Services players cover WuXi AppTec, Allucent, Altasciences, LAXAI, Lonza, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
The 鈥淔irst-in-Human (FIH) Services Industry Forecast鈥� looks at past sales and reviews total world First-in-Human (FIH) Services sales in 2024, providing a comprehensive analysis by region and market sector of projected First-in-Human (FIH) Services sales for 2025 through 2031. With First-in-Human (FIH) Services sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world First-in-Human (FIH) Services industry.
This Insight Report provides a comprehensive analysis of the global First-in-Human (FIH) Services landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on First-in-Human (FIH) Services portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global First-in-Human (FIH) Services market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for First-in-Human (FIH) Services and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global First-in-Human (FIH) Services.
This report presents a comprehensive overview, market shares, and growth opportunities of First-in-Human (FIH) Services market by product type, application, key players and key regions and countries.
Segmentation by Type:
Drugs
Medical Device
Segmentation by Application:
Pharmaceutical Companies
Contract Research Organizations (CROs)
Academic Institutions and Research Centers
Medical Device Companies
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
WuXi AppTec
Allucent
Altasciences
LAXAI
Lonza
Syneos Health
CD BioSciences
Fortrea
Certara
Evotec
Aixial Group
Quotient Sciences
Sofpromed
Spaulding Clinical
Biotrial
Crystal Pharmatech Co., Ltd
Avania
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global First-in-Human (FIH) Services 麻豆原创 Size (2020-2031)
2.1.2 First-in-Human (FIH) Services 麻豆原创 Size CAGR by Region (2020 VS 2024 VS 2031)
2.1.3 World Current & Future Analysis for First-in-Human (FIH) Services by Country/Region (2020, 2024 & 2031)
2.2 First-in-Human (FIH) Services Segment by Type
2.2.1 Drugs
2.2.2 Medical Device
2.3 First-in-Human (FIH) Services 麻豆原创 Size by Type
2.3.1 First-in-Human (FIH) Services 麻豆原创 Size CAGR by Type (2020 VS 2024 VS 2031)
2.3.2 Global First-in-Human (FIH) Services 麻豆原创 Size 麻豆原创 Share by Type (2020-2025)
2.4 First-in-Human (FIH) Services Segment by Application
2.4.1 Pharmaceutical Companies
2.4.2 Contract Research Organizations (CROs)
2.4.3 Academic Institutions and Research Centers
2.4.4 Medical Device Companies
2.5 First-in-Human (FIH) Services 麻豆原创 Size by Application
2.5.1 First-in-Human (FIH) Services 麻豆原创 Size CAGR by Application (2020 VS 2024 VS 2031)
2.5.2 Global First-in-Human (FIH) Services 麻豆原创 Size 麻豆原创 Share by Application (2020-2025)
3 First-in-Human (FIH) Services 麻豆原创 Size by Player
3.1 First-in-Human (FIH) Services 麻豆原创 Size 麻豆原创 Share by Player
3.1.1 Global First-in-Human (FIH) Services Revenue by Player (2020-2025)
3.1.2 Global First-in-Human (FIH) Services Revenue 麻豆原创 Share by Player (2020-2025)
3.2 Global First-in-Human (FIH) Services Key Players Head office and Products Offered
3.3 麻豆原创 Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 First-in-Human (FIH) Services by Region
4.1 First-in-Human (FIH) Services 麻豆原创 Size by Region (2020-2025)
4.2 Global First-in-Human (FIH) Services Annual Revenue by Country/Region (2020-2025)
4.3 Americas First-in-Human (FIH) Services 麻豆原创 Size Growth (2020-2025)
4.4 APAC First-in-Human (FIH) Services 麻豆原创 Size Growth (2020-2025)
4.5 Europe First-in-Human (FIH) Services 麻豆原创 Size Growth (2020-2025)
4.6 Middle East & Africa First-in-Human (FIH) Services 麻豆原创 Size Growth (2020-2025)
5 Americas
5.1 Americas First-in-Human (FIH) Services 麻豆原创 Size by Country (2020-2025)
5.2 Americas First-in-Human (FIH) Services 麻豆原创 Size by Type (2020-2025)
5.3 Americas First-in-Human (FIH) Services 麻豆原创 Size by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC First-in-Human (FIH) Services 麻豆原创 Size by Region (2020-2025)
6.2 APAC First-in-Human (FIH) Services 麻豆原创 Size by Type (2020-2025)
6.3 APAC First-in-Human (FIH) Services 麻豆原创 Size by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe First-in-Human (FIH) Services 麻豆原创 Size by Country (2020-2025)
7.2 Europe First-in-Human (FIH) Services 麻豆原创 Size by Type (2020-2025)
7.3 Europe First-in-Human (FIH) Services 麻豆原创 Size by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa First-in-Human (FIH) Services by Region (2020-2025)
8.2 Middle East & Africa First-in-Human (FIH) Services 麻豆原创 Size by Type (2020-2025)
8.3 Middle East & Africa First-in-Human (FIH) Services 麻豆原创 Size by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Global First-in-Human (FIH) Services 麻豆原创 Forecast
10.1 Global First-in-Human (FIH) Services Forecast by Region (2026-2031)
10.1.1 Global First-in-Human (FIH) Services Forecast by Region (2026-2031)
10.1.2 Americas First-in-Human (FIH) Services Forecast
10.1.3 APAC First-in-Human (FIH) Services Forecast
10.1.4 Europe First-in-Human (FIH) Services Forecast
10.1.5 Middle East & Africa First-in-Human (FIH) Services Forecast
10.2 Americas First-in-Human (FIH) Services Forecast by Country (2026-2031)
10.2.1 United States 麻豆原创 First-in-Human (FIH) Services Forecast
10.2.2 Canada 麻豆原创 First-in-Human (FIH) Services Forecast
10.2.3 Mexico 麻豆原创 First-in-Human (FIH) Services Forecast
10.2.4 Brazil 麻豆原创 First-in-Human (FIH) Services Forecast
10.3 APAC First-in-Human (FIH) Services Forecast by Region (2026-2031)
10.3.1 China First-in-Human (FIH) Services 麻豆原创 Forecast
10.3.2 Japan 麻豆原创 First-in-Human (FIH) Services Forecast
10.3.3 Korea 麻豆原创 First-in-Human (FIH) Services Forecast
10.3.4 Southeast Asia 麻豆原创 First-in-Human (FIH) Services Forecast
10.3.5 India 麻豆原创 First-in-Human (FIH) Services Forecast
10.3.6 Australia 麻豆原创 First-in-Human (FIH) Services Forecast
10.4 Europe First-in-Human (FIH) Services Forecast by Country (2026-2031)
10.4.1 Germany 麻豆原创 First-in-Human (FIH) Services Forecast
10.4.2 France 麻豆原创 First-in-Human (FIH) Services Forecast
10.4.3 UK 麻豆原创 First-in-Human (FIH) Services Forecast
10.4.4 Italy 麻豆原创 First-in-Human (FIH) Services Forecast
10.4.5 Russia 麻豆原创 First-in-Human (FIH) Services Forecast
10.5 Middle East & Africa First-in-Human (FIH) Services Forecast by Region (2026-2031)
10.5.1 Egypt 麻豆原创 First-in-Human (FIH) Services Forecast
10.5.2 South Africa 麻豆原创 First-in-Human (FIH) Services Forecast
10.5.3 Israel 麻豆原创 First-in-Human (FIH) Services Forecast
10.5.4 Turkey 麻豆原创 First-in-Human (FIH) Services Forecast
10.6 Global First-in-Human (FIH) Services Forecast by Type (2026-2031)
10.7 Global First-in-Human (FIH) Services Forecast by Application (2026-2031)
10.7.1 GCC Countries 麻豆原创 First-in-Human (FIH) Services Forecast
11 Key Players Analysis
11.1 WuXi AppTec
11.1.1 WuXi AppTec Company Information
11.1.2 WuXi AppTec First-in-Human (FIH) Services Product Offered
11.1.3 WuXi AppTec First-in-Human (FIH) Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.1.4 WuXi AppTec Main Business Overview
11.1.5 WuXi AppTec Latest Developments
11.2 Allucent
11.2.1 Allucent Company Information
11.2.2 Allucent First-in-Human (FIH) Services Product Offered
11.2.3 Allucent First-in-Human (FIH) Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.2.4 Allucent Main Business Overview
11.2.5 Allucent Latest Developments
11.3 Altasciences
11.3.1 Altasciences Company Information
11.3.2 Altasciences First-in-Human (FIH) Services Product Offered
11.3.3 Altasciences First-in-Human (FIH) Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.3.4 Altasciences Main Business Overview
11.3.5 Altasciences Latest Developments
11.4 LAXAI
11.4.1 LAXAI Company Information
11.4.2 LAXAI First-in-Human (FIH) Services Product Offered
11.4.3 LAXAI First-in-Human (FIH) Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.4.4 LAXAI Main Business Overview
11.4.5 LAXAI Latest Developments
11.5 Lonza
11.5.1 Lonza Company Information
11.5.2 Lonza First-in-Human (FIH) Services Product Offered
11.5.3 Lonza First-in-Human (FIH) Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.5.4 Lonza Main Business Overview
11.5.5 Lonza Latest Developments
11.6 Syneos Health
11.6.1 Syneos Health Company Information
11.6.2 Syneos Health First-in-Human (FIH) Services Product Offered
11.6.3 Syneos Health First-in-Human (FIH) Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.6.4 Syneos Health Main Business Overview
11.6.5 Syneos Health Latest Developments
11.7 CD BioSciences
11.7.1 CD BioSciences Company Information
11.7.2 CD BioSciences First-in-Human (FIH) Services Product Offered
11.7.3 CD BioSciences First-in-Human (FIH) Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.7.4 CD BioSciences Main Business Overview
11.7.5 CD BioSciences Latest Developments
11.8 Fortrea
11.8.1 Fortrea Company Information
11.8.2 Fortrea First-in-Human (FIH) Services Product Offered
11.8.3 Fortrea First-in-Human (FIH) Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.8.4 Fortrea Main Business Overview
11.8.5 Fortrea Latest Developments
11.9 Certara
11.9.1 Certara Company Information
11.9.2 Certara First-in-Human (FIH) Services Product Offered
11.9.3 Certara First-in-Human (FIH) Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.9.4 Certara Main Business Overview
11.9.5 Certara Latest Developments
11.10 Evotec
11.10.1 Evotec Company Information
11.10.2 Evotec First-in-Human (FIH) Services Product Offered
11.10.3 Evotec First-in-Human (FIH) Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.10.4 Evotec Main Business Overview
11.10.5 Evotec Latest Developments
11.11 Aixial Group
11.11.1 Aixial Group Company Information
11.11.2 Aixial Group First-in-Human (FIH) Services Product Offered
11.11.3 Aixial Group First-in-Human (FIH) Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.11.4 Aixial Group Main Business Overview
11.11.5 Aixial Group Latest Developments
11.12 Quotient Sciences
11.12.1 Quotient Sciences Company Information
11.12.2 Quotient Sciences First-in-Human (FIH) Services Product Offered
11.12.3 Quotient Sciences First-in-Human (FIH) Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.12.4 Quotient Sciences Main Business Overview
11.12.5 Quotient Sciences Latest Developments
11.13 Sofpromed
11.13.1 Sofpromed Company Information
11.13.2 Sofpromed First-in-Human (FIH) Services Product Offered
11.13.3 Sofpromed First-in-Human (FIH) Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.13.4 Sofpromed Main Business Overview
11.13.5 Sofpromed Latest Developments
11.14 Spaulding Clinical
11.14.1 Spaulding Clinical Company Information
11.14.2 Spaulding Clinical First-in-Human (FIH) Services Product Offered
11.14.3 Spaulding Clinical First-in-Human (FIH) Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.14.4 Spaulding Clinical Main Business Overview
11.14.5 Spaulding Clinical Latest Developments
11.15 Biotrial
11.15.1 Biotrial Company Information
11.15.2 Biotrial First-in-Human (FIH) Services Product Offered
11.15.3 Biotrial First-in-Human (FIH) Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.15.4 Biotrial Main Business Overview
11.15.5 Biotrial Latest Developments
11.16 Crystal Pharmatech Co., Ltd
11.16.1 Crystal Pharmatech Co., Ltd Company Information
11.16.2 Crystal Pharmatech Co., Ltd First-in-Human (FIH) Services Product Offered
11.16.3 Crystal Pharmatech Co., Ltd First-in-Human (FIH) Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.16.4 Crystal Pharmatech Co., Ltd Main Business Overview
11.16.5 Crystal Pharmatech Co., Ltd Latest Developments
11.17 Avania
11.17.1 Avania Company Information
11.17.2 Avania First-in-Human (FIH) Services Product Offered
11.17.3 Avania First-in-Human (FIH) Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.17.4 Avania Main Business Overview
11.17.5 Avania Latest Developments
12 Research Findings and Conclusion
听
听
*If Applicable.
